January 27th, 2023

The collaborative project named ‘Preclinical development and evolution of second-generation antibodies for the treatment of metastatic colorectal cancer’ has been selected to receive funding in the joint ISCIII-CDTI call for proposals in innovation linked to ‘Personalized Medicine and Advanced Therapies’.

The multidisciplinary research consortium involves strategic partners like the Group of Mechanisms of Cancer Metastasis at the Centro de Investigaciones Biológicas Margarita Salas (CIBMS), the Functional Proteomics Unit of the Functional Research Unit in Chronic Diseases (UFIEC) at Instituto de Salud Carlos III (ISCIII), the Immune Redirection research group at Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) and the company Protein Alternatives (PROALT).

The main goal of this new project is the preclinical evaluation of first and second generation specific anti-CDH17 monoclonal antibodies in different animal models of metastatic colorectal cancer (mCRC) to advance towards the immediate use in clinical trials.

‘Innovations in Personalized Medicine and Advanced Therapies’ program is part of the Vanguard Strategic Project for Economic Recovery and Transformation for Health (PERTE de Salud), which was approved by The Council of Ministers on November 30, 2021. The joint action between the Carlos III Health Institute (ISCIII) and The Center for Technological Development and Innovation (CDTI) seeks to coordinate scientific capacities with business capacities to advance faster in the development of innovative and personalized treatments.

This project is funded by the European Union ‘Recovery plan for Europe’ <NextGenerationEU>.